ASH 2021 | Genomic analysis of patients with MGUS who progress to myeloma versus those who do not

Niccolò Bolli, MD, PhD, University of Milan, ltaly, talks on his work investigating genetic evolution across the disease spectrum from monoclonal gammopathy of undetermined significance (MGUS) to active multiple myeloma, with the aim of identifying features able to predict the likelihood of progression from precursor to overt disease. His team conducted detailed genomic analysis of samples from patients with MGUS who did not progress to multiple myeloma over a long follow-up period, compared to those that did. The investigation revealed genomic abnormalities, including structural abnormalities and mutational signatures, that appeared to be closely associated with progression. For example, complex rearrangements and chromosomal deletions were noted that occurred only in patients with MGUS that progressed to myeloma. While further validation is needed, it is hoped these findings may provide the basis for a more accurate classification, using biological information to risk stratify patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.